ALX Oncology (ALXO) announced that the updated results from its Phase 2 ASPEN-06 clinical trial have been accepted for oral presentation at the 2025 American Society of Clinical Oncology, ASCO, Gastrointestinal Cancers Symposium, which will be held in San Francisco from January 23 – 25, 2025. ASPEN-06 is a randomized, multi-center, international trial evaluating evorpacept, ALX Oncology’s investigational CD47-blocking therapeutic that uniquely combines a high-affinity CD47-binding domain with an inactivated proprietary Fc domain, in combination with trastuzumab, CYRAMZA and paclitaxel against TRP alone for the treatment of patients with HER2-positive gastric/gastroesophageal junction cancer, where all patients had received an anti-HER2 agent in prior lines of therapy.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ALXO:
- ALX Oncology to host virtual event to discuss Phase 1b/2 evorpacept data
- ALX Oncology announces results from Phase 1b/2 trial
- ALX Oncology Strengthens Leadership with Key Appointment
- ALX Oncology appoints Alan Sandler as CMO
- ALX Oncology Highlights Promising Trial Results
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
